Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder

2008 ◽  
Vol 120 (3) ◽  
pp. 69-88 ◽  
Author(s):  
Matthew Brams ◽  
Alice R. Mao ◽  
Robert L. Doyle
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Hyperactivity Disorder ◽  
Long Acting

scholarly journals Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder

2017 ◽  
Vol 9 ◽  
pp. 117957351772809 ◽  
Author(s):  
Jadwiga Najib ◽  
Dexter Wimer ◽  
Julie Zeng ◽  
Kristina W Lam ◽  
Natalya Romanyak ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
English Language ◽  
Rating Scales ◽  
Post Dose ◽  
Lisdexamfetamine Dimesylate ◽  
Global Improvement ◽  
Hyperactivity Disorder ◽  
Search Terms ◽  
Long Acting

Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity disorder (ADHD) dosed once daily. Due to its long-acting properties, LDX remains pharmacologically inactive until an enzymatic process predominantly associated with red blood cells converts it to the active ingredient, d-amphetamine and the amino acid lysine. The efficacy of LDX over placebo has been demonstrated in several studies in adults with moderate to severe ADHD with significant improvements noted in ADHD rating scales, Clinical Global Improvement scores, and assessments of executive function, for all doses of LDX (30-70 mg daily). Lisdexamfetamine dimesylate has demonstrated efficacy at 14 hours post dose in adults and may be used as a long-acting stimulant for managing ADHD symptoms, which may extend late into the day. Lisdexamfetamine dimesylate has demonstrated a safety profile consistent with long-acting stimulants use. Relevant English language articles were identified through computerized searches of MEDLINE (PubMed and EMBASE) from 1995 to 2016 using the following search terms: lisdexamfetamine dimesylate, attention-deficit hyperactivity disorder, NRP104, and Vyvanse.

Relative Efficacy of Long-Acting Stimulants on Children With Attention Deficit-Hyperactivity Disorder: A Comparison of Standard Methylphenidate, Sustained-Release Methylphenidate, Sustained-Release Dextroamphetamine, and Pemoline

PEDIATRICS ◽  
1990 ◽  
Vol 86 (2) ◽  
pp. 226-237 ◽  
Author(s):  
William E. Pelham ◽  
Karen E. Greenslade ◽  
Mary Vodde-Hamilton ◽  
Debra A. Murphy ◽  
Jonathan J. Greenstein ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Sustained Release ◽  
Attention Deficit ◽  
Stimulant Medication ◽  
Continuous Performance ◽  
Continuous Performance Task ◽  
Performance Task ◽  
Double Blind ◽  
Hyperactivity Disorder ◽  
Long Acting

Twenty-two children with attention deficit-hyperactivity disorder underwent a double-blind, placebo-controlled, crossover evaluation of the efficacy of standard methylphenidate twice a day and comparable doses every morning of a sustained-release preparation of methylphenidate (SR-20 Ritalin), a sustained-release form of dextroamphetamine (Dexedrine Spansule), and pemoline. The children were participating in a summer treatment program in which they engaged in recreational and classroom activities. Dependent measures include evaluations of social behavior during group recreational activities, classroom performance, and performance on a continuous performance task. Results revealed generally equivalent and beneficial effects of all four medications. Dexedrine Spansule and pemoline tended to produce the most consistent effects and were recommended for 10 of the 15 children who were responders to medication. The continuous performance task results showed that all four medications had an effect within 2 hours of ingestion, and the effects lasted for 9 hours. The implications of these results for the use of long-acting stimulant medication in children with attention deficit-hyperactivity disorder are discussed.

Long-Acting Methylphenidate-OROS in Youths with Attention-Deficit Hyperactivity Disorder Suboptimally??Controlled with Immediate-Release Methylphenidate

CNS Drugs ◽  
2008 ◽  
Vol 22 (2) ◽  
pp. 157-170 ◽  
Author(s):  
Adrianne Faber ◽  
Michel van Agthoven ◽  
Luuk J Kalverdijk ◽  
Hilde Tobi ◽  
Lolkje T W de Jong-van den Berg ◽  
...  
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Immediate Release ◽  
Hyperactivity Disorder ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document